Clinical trials with daptomycin were halted in December 1990 because of treatment failures including two resistant Staphylococcus aureus strains. High protein binding of daptomycin (>90,%) and the lower-thanexpected concentrations in serum with the dosage regimen of 3 mg/kg of body weight every 12 h may have contributed to these failures. To evaluate the effect that higher concentrations would have on bactericidal activity measured by time-kill curves, peak and trough concentrations were estimated for dosage regimens of 3, 5, and 10 mg/kg every 12 h. MICs, MBCs, and killing curves for daptomycin and vancomycin were performed by using the estimated concentrations with four S. aureus strains obtained from patients who failed daptomycin therapy for endocarditis. MICs and MBCs of daptomycin demonstrated a greater inoculum effect than those of vancomycin; MICs and MBCs of daptomycin increased three-to fourfold, but those of vanconmycin increased only one-to twofold when the inoculum was increased from 5 x IV0 to 5 x 107 CFLJ/ml.
No pH-dependent effect on MICs or MBCs was seen. Strenuous experimental conditions were chosen: high inoculums (5 x 107 CFU/ml), extremes of pH (6.4, 7.4, and 8) , and stationary and exponentially growing organisms; and all experiments completed in the presence of pooled human serum. Daptomycin exhibited concentration-dependent killing and statistically faster kill rates than vancomycin against stationary-or exponential-growth-phase organisms. A pH-dependent decrease in activity with daptomycin was also demonstrated. Daptomycin and vancomycin produced higher kill rates against exponentially growing organisms. The results indicate that the use of higher dosage regimens with compounds similar to daptomycin may be capable of overcoming the effects of pH, high inoculum, and protein binding.
Daptomycin is derived from Streptomyces roseosporus and represents a new class of antimicrobial agents known as peptolides (acidic lipopeptide antibiotics) (3) . Daptomycin has an antimicrobial spectrum similar to that of vancomycin and teicoplanin, with activity against gram-positive aerobic and anaerobic bacteria, including methicillin-resistant staphylococci (6, 7, 14, (16) (17) (18) (19) . Daptomycin also maintains activity against vancomycin-resistant gram-positive bacteria which are being recognized increasingly as pathogens (6) . The mechanism of action appears to differ from that of vancomycin and was previously thought to be due to the inhibition of precursors to peptidoglycan synthesis, but new information indicates that membrane disruption and the inhibition of amino acid transport are the sole mechanisms of action (1) (2) (3) . Daptomycin, like aminoglycosides and quinolones, exhibits concentration-dependent bacterial killing, a characteristic not demonstrated by the glycopeptides (4, 12) .
Daptomycin was studied in early clinical trials with a dosage of 2 mg/kg of body weight per day. These trials were terminated because of failures despite seemingly adequate levels in serum. The most recent clinical trials with daptomycin were suspended because of failures in patients treated for Staphylococcus aureus endocarditis. The dosage regimen consisted of a loading dose of 6 mg/kg followed by 3 mg/kg every 12 h. Possible reasons for the previous failures have been voiced, relating to the high degree of protein binding (11) . Daptomycin is over 90% protein bound, leading to the possibility of subtherapeutic free concentrations. In addition, data from our institution indicate that the pharmacokinetic disposition of daptomycin may be altered in patients compared with that in healthy volunteers with lower peak concentrations due to an increased volume of distribution (20) . In a rabbit model of endocarditis, daptomycin was found to be equally effective to vancomycin and high-dose teicoplanin in reducing vegetation bacterial counts, with peak and trough concentrations of 75 and 20 ,ug/ml, respectively. However, despite seemingly adequate concentrations, daptomycin-and teicoplanin-resistant isolates were recovered from 2 of 16 and 1 of 16 rabbits, respectively (15) .
Endocarditis represents a unique infectious process which includes difficulties existing in both antibiotic penetration, impaired immune response, high bacterial inoculum, and bacteria in both logarithmic and stationary growth phases (21) . Therefore, we determined the bactericidal activity of daptomycin and vancomycin at an inoculum of 5 x 107 CFU/ml against stationary and exponentially growing organisms at various pHs.
In order to ascertain the effects of concentration, we performed kill curves at simulated expected peak and trough concentrations for three different dosage regimens. The serum bactericidal killing rate (SBR) of daptomycin was compared with that of vancomycin at these higher concen-ANTIMICROB. AGENTrs CHEMOTHER.
trations against four S. aureus cinical isolates obtained from patients who had failed daptomycin therapy.
MATERIAIS AND METHODS
Bacterial strains. Four S. aureus isolates obtained from patients considered to represent endocarditis treatment failures during daptomycin therapy were studied: one methicillin-resistant strain (675) and three methicillin-sensitive strains (1043-72, 135, and daptomycin-resistant 133-1).
Antibiotics. Daptomycin (lot no. SI-157-9C) and vancomycin susceptibility powders (lot no. SI-657-8R) were supplied by Eli Lilly & Co. (Indianapolis, Ind.). Stock solutions were prepared in appropriate amounts of distilled and deionized sterile water and were further diluted to the desired concentrations in the appropriate media. In a previous investigation, six patients enrolled in the phase II clinical efficacy study receiving daptomycin at a dosage of 3 mg/kg every 12 h underwent pharmacokinetic evaluation at steady state (20) .
These pharmacokinetic paratneters were analyzed with the MULTIDOSE program, which uses superposition principles to predict steady-state concentrations (26) . For the following simulated daptomycin doses given intravenously every 12 hours, the mean peak and trough concentrations were as follows: 3 mg/kg, 40 and 10 pg/ml; 5 mg/kg, 70 and 20 jig/ml; and 10 mg/kg, 150 and 40 p.g/ml. A vancomycin concentration of 20 ,g/ml was chosen as a representative concentration in serum since vancomycin does not demonstrate concentration-dependent killing (4, 10) . MIC and MBC determinations. The MIC and MBC were determined for each isolate by using a microdilution technique with PHS-SMHB at a ratio of 50 50 (24) . Inoculums of 5 x 105 and 5 x 107 CFU/ml were tested for each strain at pH 6.4, 7.4, and 8.
Protein binding. The effects of these different conditions on protein binding were determined from ultrafiltrate (UF) obtained by using the Centrifree Micropartition System (Amicon Division, WR Grace & Co., Beverly, Mass.). Samples from the beginning and end of the experiment were spun at 1,000 x g for 20 min in a fixed-angle centrifuge at 25°C, and UF was collected. Published reports and research ongoing in our laboratory indicate that this method is accurate for determining the protein binding for vancomycin and daptomycin (4, 20) . The percentage free (unbound) was calculated as the concentration of unbound protein divided by the total concentration and then multiplied by 100.
Antibiotic assay. Samples were stored at -200C until the time of assay. Concentrations of daptomycin in PHS-SMHB and UF were determined by high-pressure liquid chromatography as described elsewhere (20) . Our assay limit, coefficient of variation, and correlation coefficient for PHS-SMHB and UF were 5 and 1 p,g/ml, <5 and 9%, and 0.994 and 0.991, respectively. Vancomycin concentrations in PHS-SMHB and UF were determined by using fluorescence polarization inmmunoassay (TDx; Abbott Laboratories, Irving, Tex.) as described elsewhere (4). Our assay limit for this procedure for vancomycin is 0.6 p.g/mil; the coefficient of variation was <5% (4).
Pharnacodynamic analysis, stationary phase. S. aureus strains were grown overnight in SMHB to produce a bacterial inoculum of -2 x 109 CFU/ml and frozen in aliquots at -20°C. The antibiotics were added to SMHNI to achieve the desired concentrations. SMHB controls, which did not contain antibiotic, were also tested. Three milliliters of PHS, 2.85 ml of SMHB containing antibiotic, and 0.15 ml of thawed inoculum were combined, resulting in a 50:50 (PHS to SMHB) mixture. Strain 133-1 grew overnight to a lower maximum CFU per milliliter concentration and required an inoculum of 0.5 ml. The system was incubated on a rotator at 37°C, and a 0.1-ml aliquot was removed at time points of 0, 1, 2, 3, 4, and 6 h, appropriately diluted in normal saline, and plated onto tryptic soy agar (TSA; Difco) in duplicate. Dilutions were chosen to decrease antibiotic carryover and to target colony counts of 20 to 300 CFU per plate. CFUs were read after incubation at 37C for 18 to 24 h. Killing curves were generated depicting log1o CFU per milliliter versus time. SBRs (log1o CFU per inilliliter per hour) were calculated as the slope of the line generated from linear regression of the killing curve. The pH was determined at the 6-h time point.
Phannacodynamic analysis, exponential phase. Killing curves for this condition were performed at pH 7.4 only. The growth pattern of each clinical isolate in SMHB was plotted as log10 CFU per milliliter versus time, read spectrophotometrically at 54 nm, and plotted as log10 CFU per milliliter versus absorbance. The time to reach exponential growth was determined graphicaDly, checked spectrophotometrically, and occurred after at least 2 h of growth. After growth of 108 CFU/ml was reached, 3 ml of inoculum was added to 3 ml of antibiotic-containing SMHB. The system was divided into two equal portions to eliminate variations in temperature during aliquot removal and dilution which could affect bactericidal characteristics. The time points were changed to 0, 0.5, 1, 1.5, 2, 3, 4, and 6 h to assess more accurately the expected faster bactericidal rate. Killing curves were prepared as described above. The pH was determined at the 6-h time point for both stationary and exponential kill curves.
Statical analysis. The SBR determined from the slope of the log10 CFU per milliliter versus time kill curve was compared for daptomycin within each pH, concentration, and growth phase. Sensitive and resistant S. aureus strains were considered separately. Vancomycin SBRs were compared within pH and growth phase. Anialysis of variance was used to assess the MICs, MBCs, and SBRs for all tested conditions by Tukey's test for multiple comparisons. A P value of <0.05 was considered significant. A siginoidal Emax model was fit to the data for each strain and condition for daptomycin (9) . Because of data constraints, only preliminary information is available.
RESULTS
The MICs of daptomycin and vancomycin against each S. aureus isolate at 5 x 105 and 5 x 107 CFU/ml are shown in Table 1 . The MICs and MBCs of daptomycin and vancomycin were adversely affected by increasing inoculum (P, <0.01). Daptomycin MICs and MBCs compared with those of vancomycin at a low inoculum were not significantly different, but daptomycin MICs and MBCs were significantly higher at 5 x 107 CFU/ml (P, <0.01). This is ex- Table 2 , footnote a for a description of abbreviations.
b Compared with 150 ,ug/ml, P was <0.05.
c Compared with the stationary phase, P was <0.05.
d Compared with 20, 40, 70 and 150 pg/ml, P was <0.01.
Compared with daptomycin, P was <0.02. f Compared with daptomycin, P was <0.005; compared with the stationary phase, P = 0.07.
Ionized calcium concentrations were measured and demonstrated a pH-dependent inverse relationship. The ionized calcium concentrations in PHS-SMHB for pH 6.4, 7.4, and 8 were 1.06, 0.91, and 0.71 mM, respectively.
DISCUSSION
Daptomycin has excellent in vitro activity against methicillin-sensitive and -resistant S. aureus and other grampositive bacteria (6, 7, 14, (16) (17) (18) (19) . Treatment failures during the recent phase II trial with a dosage of 3 mg/kg intravenously every 12 h prompted this in vitro evaluation. We chose experimental conditions of high inoculum, extremes of pH, and both stationary-and exponential-growth-phase organisms to provide a more strenuous test of daptomycin's activity. These were chosen because the type of patients who failed during daptomycin therapy in the phase II trial had endocarditis. Endocarditis represents an infection with several unique characteristics; high bacterial inoculum, impaired host defenses, and bacteria with low metabolic activity in a nutritionally deficient environment (21) .
Daptomycin and vancomycin MICs and MBCs were adversely affected by inoculum, and the effect on daptomycin was more pronounced. Jones and Barry also have shown that the MICs of daptomycin increased by more than fivefold when the inoculum was increased from 5 x 105 to 1 x 107 in SMHB (14) . This is similar to the three-to fourfold increase observed here.
This study further supports earlier reports that daptomycin is highly bactericidal compared with vancomycin (10, 12, 13, 20, 22, 23 (1, 2) . Daptomycin and vancomycin displayed higher killing activities against actively growing organisms. This has been a common finding for cell wall active antibiotics (8) . However, daptomycin maintained acceptable killing activity against stationary-phase organisms. Theoretically, these would be the expected target organisms in infections such as endocarditis. This also may explain the apparent efficacy in patients who presented with bacteremia of other causes.
Daptomycin's killing activity and postantibiotic effect against S. aureus and Enterococcusfaecalis are known to be influenced by ionized calcium concentration (13) . We are aware that the use of SMHB with 25 mg/liter of Ca2" does not produce physiologic concentrations of ionized calcium. At pH 7.4, our mixture of PHS and SMHB produced an ionized calcium concentration of 0.91 mM, slightly below physiologic concentrations of 1.15 to 1.31 mM. Since the pH was varied and has an inverse relationship in vitro, we chose not to adjust the ionized calcium within each pH to physiologic concentrations. It should be pointed out that the ionized calcium concentration was within the physiologic range at pH 6.4, but daptomycin demonstrated the poorest killing activity at this level. Therefore, it appears that pH is a significant determinant of daptomycin's bactericidal activity in addition to ionized calcium.
There appear to be differences among daptomycin-sensitive S. aureus (10) . There may be unexplained strain-specific differences which can affect the bactericidal activity of daptomycin and adversely affect outcome. Removing 1043-72 from the statistical analysis did not improve our ability to detect other significant differences.
The presence of human serum or albumin has been shown to decrease the killing activity of daptomycin (12, 13, 20, 25 (4, 20) . In previous experiments in our laboratory, vancomycin killing was enhanced in a 50:50 mixture of non-heat-inactivated serum (both pooled human or patient derived) and SMHB compared with SMHB alone (4, 20) . This could have made it more difficult to detect a significant difference between daptomycin and vancomycin, although differences were still found. Previous reports have used 100% serum for performing kill curves. Growth of S. aureus is inhibited in 100% serum because of a lack of nutrients (25) . We chose to use a 50:50 mixture of SMHB and PHS which does not inhibit growth to remove this possible confounding variable.
Despite seemingly excellent in vitro activity and in vivo efficacy in animal models, daptomycin has proved ineffective against human S. aureus endocarditis in the dosage regimens administered to date. Daptomycin has been dropped from further development in the United States because of toxicity with higher-dosage regimens. This study has demonstrated that despite the harsh environmental conditions evaluated, daptomycin was capable of producing kill rates surpassing those of vancomycin.
The experience with teicoplanin may have a corollary for daptomycin. Several clinical trials with teicoplanin, also a highly protein-bound drug (-90%), were stopped because of treatment failures. The use of higher-dosage regimens, presumably producing therapeutic concentrations of free drug, appears to be efficacious and is currently being utilized in clinical trials. If lipopeptides similar to daptomycin are to be developed, studies of protein binding, concentration-dependent bactericidal activity against exponential-and stationary-growth-phase organisms, and pH effects may help determine appropriate target concentrations in serum. 
